ND0612 is designed in low-dose (ND0612L) and high-dose (ND0612H), administered subcutaneously (just under the skin) through a mini-pump, enabling 24-hour continuous LD/CD administration.
2. N. Giladi, Y. Caraco, T. Gurevich, et al. Presentation: O2114 -Pharmacokinetic profile of ND0612 (levodopa/carbidopa for subcutaneous infusion) in Parkinson’s Disease (PD) patients with motor fluctuations: results of a Phase IIa dose finding study , Eur J Neurol. 2015 Jun; 22 Suppl 1: p.66.